The 29 most recent market catalysts affecting $INSM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
H.C. Wainwright Assumes Coverage of Insmed with Buy Rating
H.C. Wainwright & Co. has assumed coverage of Insmed Incorporated, assigning a 'Buy' rating and a price target of $220 per share. This represents a significant premium over the sto…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy Rating on Insmed, Lowers Price Target to $201
Guggenheim maintained its 'Buy' rating on Insmed, signaling continued positive sentiment towards the company. However, the price target was slightly lowered from $205 to $201, a mo…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Adjusts Price Target on Insmed to $158 From $154
Mizuho Securities has adjusted its price target for Insmed (INSM) upwards from $154 to $158, maintaining an 'Outperform' rating. This indicates a slightly more optimistic outlook f…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 75
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Insmed announced a narrower net loss for the third quarter of 2026 and, more significantly, raised its full-year 2026 revenue guidance. The company specifically increased its outlo…
Oct 21, 2026
Market Technicals
Bearish
Impact 55
Top 3 Health Care Stocks That Could Blast Off In October
The filing identifies three healthcare stocks – Insmed Inc (INSM), Axsome Therapeutics Inc (AXSM), and Arrowhead Pharmaceuticals Inc (ARWR) – as being oversold based on their RSI v…
Oct 12, 2026
Market Technicals
Bearish
Impact 65
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
The filing reports multiple analyst downgrades for five different companies: UWM Holdings, Enact Holdings, Roivant Sciences, Insmed, and Monday.Com. These downgrades indicate a shi…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target
HC Wainwright & Co. analyst Andrew S. Fein has reaffirmed a 'Buy' rating for Insmed (INSM) and established a $220 price target. This action signals continued bullish sentiment from…
Oct 5, 2026
Corporate Catalyst
Bearish
Impact 75
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed announced the departure of its CFO, Sara Bonstein, effective October 30th. CFO transitions, especially after a significant tenure, often create uncertainty and can lead to s…
Oct 5, 2026
Corporate Catalyst
Bearish
Impact 85
Insmed shares are trading lower after the company reaffirmed its FY26 revenue guidance. Also, CFO Sara Bonstein will step down.
The reaffirmed FY26 revenue guidance, while not a downgrade, likely failed to meet investor expectations for an upward revision, suggesting a lack of accelerated growth. This, coup…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 65
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Insmed's 8-K filing reaffirms its full-year 2026 revenue guidance for BRINSUPRI and ARIKAYCE. This is significant because it signals the company's continued confidence in its opera…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Insmed, Lowers Price Target to $207
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Insmed, signaling continued confidence in the company's fundamentals and future growth. However, the price target…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target
Goldman Sachs, a prominent investment bank, has reinstated its 'Buy' rating on Insmed and assigned a $188 price target. This action signals a strong vote of confidence from a major…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 55
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Roth Capital analyst Adam Walsh reiterated a 'Buy' rating for Insmed, signaling continued positive sentiment towards the company. However, the price target was lowered from $212 to…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 75
Insmed To Present Five Abstracts At ERS Congress 2026, Including Late-Breaking Phase 3b ENCORE Data On ARIKAYCE In Newly Diagnosed MAC Lung Disease On September 6
This headline is a significant corporate catalyst for Insmed (INSM) due to the upcoming presentation of late-breaking Phase 3b data for ARIKAYCE in newly diagnosed MAC lung disease…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed Announces Japan's Ministry Of Health, Labour And Welfare Approved BRINSUPRI For Non-Cystic Fibrosis Bronchiectasis In Patients 12 Years And Older
The approval of BRINSUPRI for non-cystic fibrosis bronchiectasis in Japan is a major win for Insmed. This expands the drug's addressable market significantly beyond its previous in…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175
JP Morgan, a major investment bank, has updated its coverage on Insmed. While the 'Overweight' rating suggests a continued positive long-term view on the stock, the slight reductio…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195
Truist Securities analyst Danielle Brill reaffirmed a 'Buy' rating for Insmed and raised the price target from $185 to $195. This action signals a strengthened positive outlook fro…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Insmed and raised the price target from $161 to $169. This action signals a positive outlook from a promin…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170
Evercore ISI Group, a prominent investment bank, has maintained its 'Outperform' rating on Insmed and raised its price target from $160 to $170. This action signals continued confi…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Thursday's Pre-Market Session
The filing details pre-market trading activity for 12 healthcare stocks, with several experiencing dramatic price swings. The primary catalyst for many of these movements, both pos…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
This headline represents a significant corporate catalyst for Insmed. Better-than-expected financial results and an upward revision of future sales guidance directly impact investo…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate
Insmed announced a highly positive Q2 earnings report, with losses per share of $(0.06) significantly beating the $(0.73) estimate and sales of $425.486 million far exceeding the $…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est
Insmed (INSM) has announced a substantial increase in its fiscal year 2026 sales outlook, moving from a range of $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion. Thi…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
The filing reports that several Wall Street analysts have initiated coverage on five different companies, with all ratings being positive ('Outperform' or 'Buy'). This is significa…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192
BMO Capital's initiation of coverage on Insmed with an Outperform rating and a $192 price target is a significant positive development for the company. Analyst coverage, especially…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
Insmed reported encouraging 12-month data from an open-label extension study for TPIP, its inhaled drug for pulmonary arterial hypertension (PAH). The data showed sustained improve…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reduction, And No Newly Identified Safety Signals In PAH
Insmed has released positive 12-month data from its open-label extension study for TPIP, a drug for Pulmonary Arterial Hypertension (PAH). The data shows sustained improvement in e…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Insmed and raised the price target from $160 to $161. This action signals continued bullish sentiment from…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.